McKesson Corporation Overview
Pro stress-test →McKesson is America's leading pharmaceutical wholesaler and healthcare services company, controlling ~41% of the U.S. drug distribution market. The company has transformed from a traditional distributor into a diversified healthcare platform integrating oncology services, specialty pharmaceuticals, medical-surgical solutions, and technology platforms.
Strategic Profile
Pro stress-test →McKesson's competitive advantage rests on its dominant U.S. Oncology Network (acquired 2010), which provides integrated clinical services and supply chain capabilities unavailable to rivals. By divesting European operations (January 2026) and planning to spin off its medical-surgical segment, management is focused on high-margin specialty pharmaceutical and oncology markets where demand is accelerating.
Competitive Landscape
Pro stress-test →McKesson faces a "Big Three" oligopoly with Cencora (35% share) and Cardinal Health (22% share). While Cencora maintains international strength, McKesson's oncology dominance and U.S.-focused strategy provide superior specialty drug positioning. The three players control >90% of U.S. pharmaceutical wholesale, creating structural pricing power and high barriers to entry.
Industry Context
McKesson Corporation operates in Pharmaceutical & Medical Distribution; Healthcare Services.
Key facts
Founded: 1833 · Headquarters: Irving, Texas · Revenue: $106.2B (Q3 FY2026 annualized) · Market cap: $92.6B